Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jeffrey Arcara is Chief Business Officer at Corvus Pharmaceuticals. OQRO lists 4 transactions filed with the SEC under this name, the latest on Nov 13, 2026, each linked to the official Form 4.
Chief Business Officer
Disclosures on record
4
Companies involved
1
Corvus PharmaceuticalsCRVS
4 disclosures · Nov 2026 · 4 bought
Nov 12, 2026Bought~$5.5Kdisclosed Nov 13
DetailsOfficial recordNov 13, 2026Bought~$5.2K
DetailsNov 13, 2026Bought~$5.4K
DetailsOfficial recordNov 11, 2026Bought~$34Kdisclosed Nov 13
DetailsOfficial recordAs of the latest filing on , Jeffrey Arcara reported holding 4,500 shares of Corvus Pharmaceuticals (CRVS), worth about $48K at the last close of $11 (Nov 13, 2026). In the last 12 months, Jeffrey Arcara bought $50K in 4 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals CRVS | 4,500 | 4,500 direct | $11 | $48K | Nov 13, 2026 |
Is this Jeffrey Arcara’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 13, 2026, Jeffrey Arcara reported holding 4,500 shares of Corvus Pharmaceuticals (CRVS). At the last close of $11 on Nov 13, 2026, that is about $48K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Jeffrey Arcara reported 4 open-market purchases worth $50K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Jeffrey Arcara bought shares on the open market in 2026.
In SEC filings since 2026: the latest open-market purchase is from 2026; no open-market sale is on record.
Corvus Pharmaceuticals (CRVS), from 2026 to 2026: 4 purchases and 0 sales.
Jeffrey Arcara bought shares on the open market in 2026.
Jeffrey Arcara reported 4 open-market purchases and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $50K4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Jeffrey Arcara reported 4 open-market purchases and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
